SureTrader
Home > Boards > US Listed > Medical - Drugs >

Apricus Biosciences, Inc. (APRI)

APRI RSS Feed
Add APRI Price Alert      Hide Sticky   Hide Intro
Moderator: ash111
Search This Board: 
Last Post: 1/14/2018 1:27:03 PM - Followers: 206 - Board type: Free - Posts Today: 0

Apricus Biosciences, Inc. (APRI) 

 

 

http://www.apricusbio.com/

 

 

 

 

Company Address:

11975 El Camino Real, Suite 300
San Diego, CA 92130
T (858) 222-8041

 CIK:   0001017491

Apricus Website:    http://www.apricusbio.com/index.html

 

 
 

NexACT® - Multi-Route Drug Delivery Technology

NexACT® Multi-Route drug delivery technology facilitates compounds crossing the lipid bilayer and yet biodegrades in vivo to natural amino acids and natural fatty acids.

This technology is useful for:
  • Penetrating, proprietary, topical & transdermal formulations.
    Improving oral bioavailability of poorly soluble, poorly permeating compounds (BCS class 2-4)
    Delivering siRNA therapeutics into the cells; in vivo validated
    Development of more effective, penetrating cosmeceutic formulations
    Preservative

The safety and permeation properties of this proprietary drug delivery technology was demonstrated in the Vitaros® product which was approved for the treatment of erectile dysfunction in November 2010 by Health Canada, and approved by the European Union in June 2013.  Vitaros has been launched in all European Union countries by partner pharmaceutical companies.  Additional agreements for marketing Vitaros have been established.  For more information see the company's most recent 10K SEC filing.

In September 2015 the company anounced an agreement with Allergan to reacquire marketing rights for Vitaros in the U.S.  The company expects to resubmit a filing for FDA approval of Vitaros in the second half of 2016.  For more information see the company's most recent 10K SEC filing.


The company expects to initiate a Phase IIb clinical trial for RayVa to treat Reynaud's Syndrome in the second half of 2016.

In October 2014, the company acquired U.S. development and licensing rights to Fispemifene, a Selective Estrogen-Receptor Modulator (SERM) for treatment of secondary hypogonadism.  In March 2016 the company discontinued development Fispemifene after disappointing Phase IIb results.
.

 Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001017491&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Share Structure:
Outstanding Shares
 61,78M

Authorized Shares
75,000,000
  

Investor Relations:
ir@apricusbio.com
Tel: +1-858 222-8041

Matthew Beck
The Trout Group
:(646)378 2933

 

 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 


                                                                           
Image result for vitaros                                                  

Image result for vitaros

SureTrader
APRI
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
APRI News: Statement of Changes in Beneficial Ownership (4) 01/08/2018 04:05:01 PM
APRI News: Statement of Changes in Beneficial Ownership (4) 01/08/2018 04:04:33 PM
APRI News: Statement of Changes in Beneficial Ownership (4) 01/08/2018 04:04:33 PM
APRI News: Statement of Changes in Beneficial Ownership (4) 01/08/2018 04:04:08 PM
APRI News: Statement of Changes in Beneficial Ownership (4) 01/08/2018 04:03:42 PM
PostSubject
#27461  Sticky Note $heff: $APRI..$2.00 cheap PDUFA play 2/17/18 w/ a ash111 01/04/18 04:56:42 PM
#27511   Nice! so many positive posts Quite a change mecosmo2 01/14/18 01:27:02 PM
#27510   thanks, GLTA eicoman 01/14/18 12:05:40 PM
#27509   Solid DD for APRI much appreciate. ash111 01/14/18 12:03:46 PM
#27508   thank you eicoman and (also new and old-timers kei 01/13/18 09:40:50 PM
#27507   Thanks Eman. And Mean Gene,I know you're an oldcoach19 01/13/18 08:20:37 PM
#27506   good point gene - if allergan jumps in eicoman 01/13/18 04:33:30 PM
#27505   Old Coach, it sure has been a long eicoman 01/13/18 04:30:21 PM
#27504   Old Coach I have been in this investment mean gene 01/13/18 04:27:19 PM
#27503   I shouldn't have said Trump, becasue faster approvals eicoman 01/13/18 04:23:10 PM
#27502   Eman-You , Aprilov, myself and a few others oldcoach19 01/13/18 01:59:26 PM
#27501   Agree thanks and good summary stock_observer_77 01/13/18 01:28:30 PM
#27500   God bless the president. PuuliTuku 01/13/18 12:53:38 PM
#27499   Good data = faster approvals with Trump FDA eicoman 01/13/18 12:29:16 PM
#27498   It’s all about the data which looks great eicoman 01/13/18 12:19:35 PM
#27497   excellent review post, eicoman. kei 01/13/18 11:33:38 AM
#27496   After the Nov 2016 Type B meeting the eicoman 01/13/18 08:32:00 AM
#27495   Since PH3 trials, even in the 2008 CRL, eicoman 01/12/18 09:19:53 PM
#27494   Sure ash111 01/12/18 05:11:49 PM
#27493   You still in ash ? peterus 01/12/18 03:37:25 PM
#27492   Erectile dysfunction drugs market This market was mecosmo2 01/11/18 12:25:52 PM
#27491   That is only for Vitaros , does not Aprilov 01/11/18 07:43:25 AM
#27490   Assuming Allergan uses their opt in, that will tjguy 01/11/18 01:05:09 AM
#27489   It can also be announced earlier so it carlodb1978 01/10/18 02:43:13 PM
#27488   We are getting near D day Apricus Biosciences mecosmo2 01/10/18 12:39:41 PM
#27487   Thanks Eman. As usual,very thorough explanation. Sometimes my oldcoach19 01/09/18 08:07:32 AM
#27486   Good dd thanks peterus 01/09/18 02:24:20 AM
#27485   NICE! Sugarplum 01/08/18 10:12:56 PM
#27484   Approval of Vitaros is an approval of DDAIP, eicoman 01/08/18 09:27:13 PM
#27483   yes, I think it's 80 maybe 90% chance, eicoman 01/08/18 09:25:34 PM
#27482   Vitaros only needs to prove safety of DDAIP eicoman 01/08/18 09:17:16 PM
#27481   Eman-do you think we have better than a oldcoach19 01/08/18 09:12:06 PM
#27480   Efficacy and CMC issues have been addressed, this eicoman 01/08/18 09:05:15 PM
#27479   Here's the most important slide from the new eicoman 01/08/18 08:57:55 PM
#27478   voted a bonus for the directors -lol oldcoach19 01/08/18 06:48:09 PM
#27477   Check latest SEC filings , and it looks mecosmo2 01/08/18 05:58:54 PM
#27476   No dulution options at 2.21 which is great Aprilov 01/08/18 04:42:06 PM
#27475   looks like conversion of stock options, not dilution eicoman 01/08/18 04:24:55 PM
#27474   are you talking about the recent bonuses oldcoach19 01/08/18 04:20:06 PM
#27473   Aske co peterus 01/08/18 04:15:08 PM
#27472   what dilution oldcoach19 01/08/18 04:07:29 PM
#27471   Dilution im out will be back peterus 01/08/18 03:59:40 PM
#27462   Up 9% in pre market ... Aprilov 01/05/18 08:14:04 AM
#27461   $heff: $APRI..$2.00 cheap PDUFA play 2/17/18 w/ a ash111 01/04/18 04:56:42 PM
#27460   That's the best part of a low float. :-) Sugarplum 01/04/18 04:11:46 PM
#27459   crazy finish today oldcoach19 01/04/18 04:10:00 PM
#27458   Think ceo was buying today peterus 01/04/18 01:12:41 PM
#27457   To match selling peterus 01/04/18 01:00:25 PM
#27456   SEC filing . .ir.apricusbio.com/phoenix.zhtml?c=118007&p=IROL-sec mecosmo2 01/04/18 08:43:17 AM
#27455   You Borne like that or just a ashole ? peterus 01/03/18 10:53:21 PM
#27454   Blow me!!!! Aprilov 01/03/18 09:12:10 PM
PostSubject